Skip to main content
. 2021 Sep 13;81(21):5572–5581. doi: 10.1158/0008-5472.CAN-20-3242

Figure 2.

Figure 2. Inhibiting OXPHOS results in broad tumor in a range of TNBC PDXs developed from residual disease. Ten TNBC PDXs were treated with IACS-10759 (5 mg/kg, orally, 5 days on 2 days off). Cohorts of 2–4 mice were used for this initial screening. IACS-10759 stabilized disease (<20% median change from baseline) for at least 21 days in four PDXs and one PDX regressed to be immeasurable disease. Only one of five BL1 PDXs grew more than >20% in 21 days. Means ± SEM are shown.

Inhibiting OXPHOS results in broad tumor in a range of TNBC PDXs developed from residual disease. Ten TNBC PDXs were treated with IACS-10759 (5 mg/kg, orally, 5 days on 2 days off). Cohorts of 2–4 mice were used for this initial screening. IACS-10759 stabilized disease (<20% median change from baseline) for at least 21 days in four PDXs and one PDX regressed to be immeasurable disease. Only one of five BL1 PDXs grew more than >20% in 21 days. Means ± SEM are shown.